Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
Survey findings from the “Owning HIV” campaign show the need for proactive education.
Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.
The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.
A new survey and educational campaign called “Owning HIV” offer insight.
Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.
Stop me if you’ve heard this one before.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
The president tweeted a swift retort to the African-American head of Merck.
Trials of immunotherapy drug for multiple myeloma suspended after patient deaths.
HIV stigma is still present, but more black women are sharing their stories.
Two new treatments have hit the market, offering more options for those with genotypes 3 and 4.
Merck has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of its single-tablet hepatitis C...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.